Introduction: Hybrid anticancer drugs are of great therapeutic interests as they can potentially overcome most of the pharmacokinetic drawbacks encountered when using conventional anticancer drugs. In fact, the future of hybrid anticancer drugs is very bright for the discovery of highly potent and selective molecules that triggers 2 or more cytocidal pharmacological mechanisms of action acting in synergy to inhibit cancer tumor growth.
Introduction
This review presents the most recent advances in the design and development of hybrid anticancer agents. This type of design was comprehensively reviewed in 2009 by Gediya et al. [1] and, in 2007 by Viegas-Junior et al. [2] . As a general rule, the review showcases the most current work in the field. Consequently, molecular structures already described in the previous reviews will not be addressed and only hybrids recently published in the literature will be discussed at the exception of hybrids required to illustrated significant elements of the discussion. Moreover, for sake of clarity and conciseness, only the most promising and potent hybrids will be described. The goal of this review is also to assist and guide the scientific community to design even better hybrid anticancer drugs for the next generation of cancer treatments.
Hybrid drug design is in constant evolution and remains essential for the discovery of innovative and potent anticancer drugs. To that end, several research groups are devising and testing new chemical and biochemical strategies for their development. This review is divided into sections that take into account two main ways by which hybrid anticancer molecules can be designed and prepared: (i) merge and blend haptophoric moieties of different drugs and (ii) combine two or several entire drugs together. Some hybrids use both design approach and are therefore difficult to classify in one or the other category.
The first approach that merges and blends haptophoric moieties of different drugs used to design new anticancer hybrids is based on the ability of a combination of haptophoric moieties on a new molecular structure to retain their affinity and activity for the biological targets. This concept is achieved using two strategies: (i) merging of two haptophoric groups from two different drugs acting through the same mechanism of action and (ii) Fortin 
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merging of haptophoric groups from two drugs acting through different mechanisms of action.
The second approach combines two or several entire drugs together (combi-molecules) directly or connected through a linking arm. Moreover, the connection can be achieved using cleavable or non-cleavable linkages. The connection of two molecular entities through non-cleavable linking arms is also based on the ability of the different molecules to retain their biological activity and their specific and respective affinity for their biological targets. On the opposite, the approach using cleavable bond is based on the release of two parental molecular structures under physiological or the enzymatic conditions that prevail at site of activity aims: to either improve poor pharmacokinetic properties of the anticancer drugs to slowly deliver the two therapeutic entities in the body (e.g. ester, amide or carbamate) or to improve the selectivity and the antineoplastic activity of the drugs and to release the two drugs directly in the targeted tissues (e.g. phosphorylated DES prodrugs for prostate cancer). In this review, we chose to classify the different hybrids by the mechanism(s) of action of their constituting drugs: (i) connection of two drugs with the same mechanism of action, (ii) connecting two drugs with different mechanisms of action and (iii) connecting two drugs in the aim to target specific biological tissues.
Merging of the haptophoric moieties of different drugs
Merging haptophoric moiety of different drugs is the first strategy that has been used to design new anticancer hybrids. Table 1 shows the parental anticancer drugs and their mechanism of action used for the design of potent hybrids. The first strategy approach is the synthesis of the merging of two haptophoric groups selected from two drugs exhibiting the same cytocidal mechanism of action. This design aims to improve activity, selectivity and biopharmaceutical properties (absorption, distribution, metabolism and excretion (ADME properties)) of both parental anticancer drugs. Several anticancer hybrids designed following this concept are shown in Figure 1 . Nguyen et al. thoroughly reviewed the antitumor activity of psoropermum xanthones and sarcomelicope acridones [4] . Their review discusses also of the biological properties of several hybrids such as epoxyfuroacridone (24) and pyranoxanthone (25) . The latter are merging the haptophore of psorospermin (3) and acronycine (4), two anticancer drugs targeting DNA. The epoxyfuroacridone 24 was prepared by amalgamating the acridone moiety of 4 and the epoxyfuran of 3 whereas pyranoxanthone 25 was designed using the xanthone moiety of 3 and the pyran group of 4. Compound 24 exhibits antiproliferative activity in the nM range while compound 25 show only marginal antiproliferative activities.
Compound 26 is a new Philadelphia chromosome (Bcr-Abl) inhibitor hybrid that has been designed using molecular fragments found in FDA approved imatinib (5), dasatinib (6) and nilotinib (7) [5] namely the pyridine group of 5, the thiazol-2-amine and the 4-methyl-Nphenylbenzamide moieties of 6 and 7, respectively. Compound 26 exhibits antiproliferative activity in the nM range, which is in the same order of magnitude as nilotinib on the cancer cell lines assessed. In addition, 26 displayed similar inhibitory potency on Bcr-Abl kinase than that of nilotinib, arrested the cell cycle progression in G0/G1-phase and induced apoptosis of K562 cancer cells.
Combination of the benzamidyl moiety of MS-275 (8) in the aliphatic chain of trichostatin A (TSA, 9), two histone deacetylase (HDAC) inhibitors, lead to the generation of SK-7041 (27) [6] . Compound 27 exhibits antiproliferative activity in the low M range and is 5-9 folds more potent than vorinostat (SAHA, 10) on lung and breast cancer cell lines. This hybrid shows also time-dependent histone hyperacetylation leading successively to G2/Mphase, G1-phase arrest and ultimately to apoptosis.
Florence et al. nicely reviewed in 2008 the marine anticancer agents discodermolide (e.g 11) and dictyostatin (e.g. 12) and discussed of the preparation and the evaluation of several hybrids deriving from these antimitotics [7] . In recent years, Paterson group has synthesized several dictyostatin-discodermolide hybrids exemplified by compounds 28a,
]. This type of hybrid consists to the addition of an alkene bond and a -methyl group at positions 15 and 18 of 11 on the molecular structure of 12. These hybrids are based on the overlapping molecular structure of 12 and the semi-cyclic conformation of
11.
Compounds 28a, b show antiproliferative activity in the low nM range on several cell lines, which is in the same order of magnitude than 11, 12 and paclitaxel. Dictyostatindiscodermolide hybrids are microtubule-stabilizing agents that do not interact with Pglycoprotein and still highly cytocidal against paclitaxel-resistant cancer cell lines.
Hybrid anticancer molecules aiming to multiple biological targets
The second strategy used to merge haptophoric moieties of different drugs is to integrate 2 different drugs that are addressing separately two or multiple biological targets. Again this strategy is used to design new families of drugs to improve the pharmacokinetic and pharmacodymamic properties of the parent components as well as to synergize their mechanisms of action in a single molecular entity structure. This approach seems to disobey to conventional strategies used in medicinal chemistry where the selectivity of a molecule for a specific biological target is the cornerstone for the development of new drugs. However it is in agreement with the logic of using "chemotherapeutic cocktails" in clinic that are combining chemotherapeutic agents exhibiting different mechanisms of action (e.g. 5-fluorouracil, epirubicin, cyclophosphamide for the treatment of breast cancer) that are more effective than the same agents used alone. In addition, that approach was found to prevent chemoresistance. Therefore, polychemotherapeutic approach was translated in recent years into the design of hybrid molecules aiming to several cytocidal targets at once [10] . Consequently, several new anticancer agent hybrids were recently designed using this strategy and are shown in Figure 2 . 
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The retinoid-chalcone hybrids (34) are composed of the retinoid moiety of bexarotene (21) combined to the chalcone moiety of compound 22, two potent anticancer molecular entities [18] . Compound 34 shows antiproliferative activity in low M range on colon adenocarcinoma HT-29 cell line.
Chalcone (22) were also used by Sashidhara et al. and fuses with the coumarin ring systems (16 and 17) to generate new coumarin-chalcone hybrids (35a-c) [19] that showed antiproliferative activity in the M range on KB, C33A, MCF-7, A549 and NIH3T3 cell lines, with a superior activity on a cervical carcinoma C33A cell line.
Combination of two or several entire drugs (combimolecules)
The amalgamation of two or several entire drugs in the same molecular structure, also termed combi-molecule is the second approach used to design new anticancer hybrids.
Several anticancer drugs used for this application and their respective mechanisms of action are described in Tables 1 and 2 . Another approach to design anticancer hybrids is the formation of homodimers of anticancer drugs. This strategy is also used to improve biopharmaceutical properties such as low solubility or short plasma half-life of drugs such as artemisinin (50) . To overcome those limitations, artemisinin-guanidine hybrids (compounds 77a, b) were designed by 20 connecting two molecules of compound 50 on a guanidine water-soluble backbone [32] .
Compounds 77a, b show antiproliferative activity in the ten nM range on HT-29 cell line.
Likewise, compounds 78a, b are dimers of testosterone and have been designed to act as an "bidentate" antiandrogen that binds simultaneously to two androgen receptors, resulting in the disruption of the androgen receptor signaling pathway [33] . The dimers were linked together either by a trans or a cis but-2-enyl tether chain. The cis dimer (cis-78b) was more active than the trans counterpart (trans-78b). Compound cis-78b exhibits antiproliferative activity in the M range on prostate LNCap and PC3 cell lines and was slightly more active than cyproterone acetate, a known antiandrogen used in clinics. However, no selectivity on androgen-dependent prostate cancer cells was observed for these dimers.
Combi-molecules with different mechanisms of action
The combi-molecules were developed in the aim to exploit multi-biological targets. It is one of the most promising approaches to design highly potent, effective and useful (22) [45] . Compound 88 exhibits antiproliferative activity in the low M range on NCI anticancer cell line panel.
The planar and semi-planar ring system of pyrene (59) 
Combi-molecules in the aim to target specific biological tissues
The combi-molecule strategy aims to the vectorization of anticancer drugs to target specific tissues is also a promising method to design highly effective, non-toxic and useful hybrids.
Unfavorable biopharmaceutical properties such as inadequate biodistribution, low tissue penetration, and poor tropism for cancer cells are major limitations that prevent most drugs to reach freely the cancer tissues or to be effective, despite high in vitro potency. This Compound 97 is a hybrid connecting also aromatic nitrogen mustards (40) (41) (42) and tyrosine that was designed to mimic the estradiol nucleus [55] . Compound 97 exhibits antiproliferative activity in the M range on prostate, breast, ovarian and uterine cancer cell lines and was slightly more active than chlorambucil (41).
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Figure 5b. Molecular structures of other combi-molecules targeting specific biological tissue. On one hand, etoposide (63) is a potent semi-synthetic topoisomerase II inhibitor deriving from podophyllotoxin. On the other hand, the polyamines transport system is frequently expressed in cancer cells. The polyamine-etoposide hybrid 100 (F14512) was designed by replacing the C4 glycosidic moiety of etoposide by a sperminyl chain in the aim to exploit the polyamines transport system to favor its accumulation into the cancer cells [58] .
Compound 100 displays antiproliferative activity on a large panel of tumor cell lines and are more active than 63 [59, 60] . Moreover, compound 100 is more active on cells expressing polyamines transport system and induces cell death by non-apoptotic and senescence-type pathways.
Aziridine (64) is another privileged cytocidal molecular structure found in mitomycin C and tiotepa and exhibiting interesting anticancer properties. Nitroxyl-aziridine hybrid (compound 101) was designed by linking the aziridinyl to nitroxyl moiety (compound 65), a stable radical species recognized for its selective accumulation in mice melanotic melanomas [61] . Despite that the authors claimed that the cytotoxicity of this hybrid is not observed, no data are shown to support this statement. 
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Conclusion
This review shows the various fashions by which a hybrid anticancer agent can be designed. We classified the hybrids into several categories according to their construct, same or different drugs and their intended targets (or mechanism(s) of action) being single, multiple or simply as vectorized hybrids. Hence, there are numerous ways to make hybrids.
This area of research presents great interest to the scientific community and is in constant expansion. We have focused only on the most recent advances in the field. It is obvious that interesting results are obtained by the construction of hybrids. In many cases, not only the biological activity is enhanced but also the selectivity is improved and the toxicities diminished. It is also clear that the hybrid themselves, its entire structure, can provide 32 additional biological properties that only the combination of drugs can do. This review shows the feasibility and great potential of the hybrid approach. The final goal is to further improve the design of the hybrid anticancer agents. This goal is in our reach. To conclude, imagination and creativity are key elements to construct a successful hybrid anticancer agent.
Expert Opinion
This review presents the latest development in the design of hybrid and combi-molecule anticancer drugs. The overall objective underlying their development is to build molecules merging two molecular fragments recognized for their individual anticancer activity towards definite targets in the cancer cells to achieve improved activity, selectivity and toxicity of anticancer agents in the aim to reduce the incidence, the mortality and morbidity outcomes of that disease. It is clear that a single agent having the capacity of interacting with several key biological targets in the cell might show significant and even synergetic anticancer properties than targeting single biological target.
The general strategy for the design of such hybrid anticancer drugs is relatively straightforward. Firstly, it involves the structure of known anticancer agent by blending it or simply linking it to a carrier molecule (or another anticancer drug) that target cancer cells more efficiently via a receptor or specific cellular processes leading to improved and even synergized biological properties. There are a number of potential advantages of hybrid anticancer drugs for the patient. Firstly, they have the ability to increase the specificity and strengthen the potency of the anticancer agents. Furthermore, they allow a reduction of the dose and the toxic side effects due to the treatment and offer a synergy between multiple anticancer mechanisms in the cells leading to apoptosis. Additionally, hybrid anticancer 33 drugs allow for a reduction of the induction of chemoresistance mechanisms in tumor and increase the chance of successful treatment.
It should be said that the requirements to design such a hybrid drug are quite evident as not only do they have the potential for high affinity towards the targeted receptor(s) or targeted molecular mechanism(s) but they also have the potential for in vitro and in vivo selectivity on cancer cells. There is also an easiness of synthesis (few and efficient chemical steps are crucial for future commercial development as well as the potential for large-scale production. It should also be said that there is, as always, the potential for intellectual property (IP) protection.
In addition, it must be borne in mind that the future success for the drug targeting approaches will be the use of "blended" or "fully-integrated" chemical structures such as So, the future directions for the construct of hybrid anticancer molecules can be divided into two main categories: "fully-integrated" and "vectorized" hybrids. The goal of these hybrid anticancer molecules is to obtain derivatives that will act synergistically on cancer cells. Clearly, the "fully-intagrated" hybrids present great potential as they often lead to relatively smaller hybrids and thus more drug-like compounds [69] . However, the amalgamation of two (or more) different components retaining their respective biological properties can be challenging. This strategy is at its infancy and needs to be further investigated. On the other hand, the synthesis of "vectorized" hybrids is relatively easier.
But, yet again the retention of the properties of the carrier moiety as well as the anticancer moiety can be difficult. In the future, we will see refined design where the carrier molecule has high affinity for its cognate receptor and where the anticancer moiety possesses higher biological activity than the parent drug itself. Such combination will lead to new, more selective and more efficient anticancer therapies devoid of side effects. Finally, successful development of a hybrid drug will also be achieved following the requirements of design described above. Obviously, work is in progress in this field and the future is bright. Only imagination is the limit to drug development.
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